Abstract

The present work exemplifies how parameter identifiability analysis can be used to gain insights into differences in experimental systems and how uncertainty in parameter estimates can be handled. The case study, presented here, investigates interferon-gamma (IFNγ) induced STAT1 signalling in two cell types that play a key role in pancreatic cancer development: pancreatic stellate and cancer cells. IFNγ inhibits the growth for both types of cells and may be prototypic of agents that simultaneously hit cancer and stroma cells. We combined time-course experiments with mathematical modelling to focus on the common situation in which variations between profiles of experimental time series, from different cell types, are observed. To understand how biochemical reactions are causing the observed variations, we performed a parameter identifiability analysis. We successfully identified reactions that differ in pancreatic stellate cells and cancer cells, by comparing confidence intervals of parameter value estimates and the variability of model trajectories. Our analysis shows that useful information can also be obtained from nonidentifiable parameters. For the prediction of potential therapeutic targets we studied the consequences of uncertainty in the values of identifiable and nonidentifiable parameters. Interestingly, the sensitivity of model variables is robust against parameter variations and against differences between IFNγ induced STAT1 signalling in pancreatic stellate and cancer cells. This provides the basis for a prediction of therapeutic targets that are valid for both cell types.

Highlights

  • Progression of pancreatic cancer (PC) is accelerated by an extended fibrosis, which has been linked to the activation of pancreatic stellate cells (PSC) [1,2,3]

  • The experimental time series and the model simulations revealed two major differences between PSC and PC summarized in Figure 2: A) Rapid initial STAT1 phosphorylation in PSC

  • We focus on parameters, which based on their position in the biochemical network, could be related to the different experimental profiles of STAT1 and phosphorylated STAT1 between PSC and PC after stimulation with IFNc

Read more

Summary

Introduction

Progression of pancreatic cancer (PC) is accelerated by an extended fibrosis, which has been linked to the activation of pancreatic stellate cells (PSC) [1,2,3]. IFNc acts as an antagonist of PSC activation and displays inhibitory effects on PC growth by inducing the STAT1 signalling pathway in both cell types [4,5]. While the qualitative effects of IFNc were the same in cancer and stellate cells, a quantitative analysis revealed significant differences. IFNc inhibited PSC proliferation more efficiently than tumour cell growth. The stronger biological effect of IFNc in PSC correlated with a more pronounced nuclear accumulation of STAT1 in the stroma cells [4,5,6], raising the question which molecular mechanisms are underlying these observations

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call